Why infection and immunity matter for Florida’s cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In Florida, cancer is part of daily life for thousands of families. It is the state’s second-leading cause of death. Each year, an estimated 115,000 Floridians receive a new cancer diagnosis and certain preventable or virus-linked cancers continue to impose avoidable burdens on communities across the state.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Eduardo Sotomayor, MD
Vice president and executive director, Tampa General Hospital Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 
Eduardo Sotomayor, MD
Vice president and executive director, Tampa General Hospital Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login